Targeting myeloid-inflamed tumor with anti-CSF-1R antibody expands CD137+ effector T-cells in the murine model of pancreatic cancer

BACKGROUND: The pancreatic cancer vaccine, GVAX, induces novel lymphoid aggregates in the otherwise immune quiescent pancreatic ductal adenocarcinoma (PDAC). GVAX also upregulates the PD-1/PD-L1 pathway, and a pre-clinical model demonstrated the anti-tumor effects of combination GVAX and anti-PD-1 a...

Descripción completa

Detalles Bibliográficos
Autores principales: Saung, May Tun, Muth, Stephen, Ding, Ding, Thomas, Dwayne L., Blair, Alex B., Tsujikawa, Takahiro, Coussens, Lisa, Jaffee, Elizabeth M., Zheng, Lei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6234697/
https://www.ncbi.nlm.nih.gov/pubmed/30424804
http://dx.doi.org/10.1186/s40425-018-0435-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6234697/
https://www.ncbi.nlm.nih.gov/pubmed/30424804
http://dx.doi.org/10.1186/s40425-018-0435-6

Ejemplares similares